Dr. Shivraj Sohur joined ONO PHARMA USA, INC. in June 2021, serving as the Vice President, Neurology Clinical Development. He leads neurology clinical development activities in the U.S. and globally while providing medical and strategy input on ONO PHARMA USA, INC.’s various clinical development projects. 

With a two-decade career focused on the treatment of neuropsychiatric disorders, Shiv has held a variety of leadership positions, most recently with Alexion Pharmaceuticals, where he was a clinical lead in a Guillain Barré Syndrome III Study in Japan, culminating in Sakigake fast-track and Orphan Drug designations. Prior to joining Alexion, Shiv worked for Alkermes and Pfizer, where he served in a variety of roles, each leading to significant accomplishments in neuroscience programs. 

Shiv earned his M.D. and Ph.D. from Vanderbilt University in Nashville, TN, and holds a B.S. in Biology and Chemistry from Angelo State University in San Angelo, Texas. In addition to his academic credentials, Shiv is on the faculty at Harvard Medical School and continues to be a part-time faculty in Neurology with a sub-specialization in Movement Disorders, practicing at Massachusetts General Hospital in Boston, MA.